**Supplemental Digital Content 12: Ocular (≥5 % in any group) and nonocular adverse events up to month 12 suspected to be related to the ocular injection (Safety set\*)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Preferred term, n (%)** | **Ranibizumab 0.5 mg (n = 119)** | **Sham with ranibizumab 0.5 mg(n = 52)** | **Sham without ranibizumab 0.5 mg (n = 7)** | **Total(N = 178)** |
| **Ocular AEs, total** | **15 (12.6)** | **12 (23.1)** | **1 (14.3)** | **28 (15.7)** |
| Conjunctival hemorrhage | 7 (5.9) | 6 (11.5) | 0 | 13 (7.3) |
| Foreign body sensation in eyes | 1 (0.8) | 1 (1.9) | 1 (14.3) | 3 (1.7) |
| Ocular hyperemia  | 1 (0.8) | 1 (1.9) | 1 (14.3) | 3 (1.7) |
| **Nonocular AEs, total** | **0** | **0** | **1 (14.3)** | **1 (0.6)** |
| Headache | 0 | 0 | 1 (14.3) | 1 (0.6) |
| \*Consisted of all adult patients who received at least one application of study treatment and had at least one post-baseline safety assessment.Preferred terms are sorted in descending order of frequency of the ranibizumab 0.5 mg group. A patient with multiple occurrences of a preferred term was counted only once in the preferred term row. AE, adverse event |